

## **Supplementary disclosures and information about agenda item 5 (Supervisory Board elections)**

Disclosures pursuant to Section 125 (1) Clause 5 AktG on memberships in other statutory supervisory boards and comparable domestic and foreign controlling bodies of business enterprises



### **Dr. Anna C. Eichhorn**

Dr. Anna C. Eichhorn is not a member of any other statutory supervisory boards.

Dr. Anna C. Eichhorn is a member of the following comparable domestic and foreign controlling bodies of business enterprises.

- Member of the Supervisory Board of the Frankfurter Innovationszentrum Biotechnologie GmbH (FiZ), Frankfurt am Main

### **Curriculum vitae of the proposed candidate Dr. Anna C. Eichhorn**

Dr. Anna C. Eichhorn was born in 1972 in Frankfurt am Main, Germany. After a foundation course in chemistry she received a degree in biochemistry from the Johann Wolfgang Goethe University in Frankfurt am Main in 1998. The academic degree of Disputation followed in 2003. In 2001, Dr. Eichhorn founded the company Humatrix AG in Frankfurt am Main together with partners, assuming the role of Chief Technology Officer (CTO). She has been Chief Executive Officer (CEO) of Humatrix AG since 2012.

In a scientific environment, Dr. Eichhorn acts as a Management Board member of the House of Pharma & Healthcare Association and as Deputy CEO of the Rhine-Main Healthcare Sector Initiative Association – both based in Frankfurt am Main. She is also a scientific consultant to the European Journal of Clinical Pharmacology (EJCP).

Dr. Eichhorn has been a member of the BRAIN Supervisory Board since 9 March 2017 and is currently Deputy Chair of the Supervisory Board

In addition to the above information, it is declared with regard to C.13 of the German Corporate Governance Code that, in the Supervisory Board's opinion, Dr. Anna C. Eichhorn has no other personal or business relationships with the Company or its Group companies, the executive bodies of the Company or a shareholder with a material interest in the Company, that would require disclosure under this provision. In the Supervisory Board's opinion, Dr. Anna C. Eichhorn is regarded as independent in the meaning of the German Corporate Governance Code. Moreover, the Supervisory Board has assured itself of the proposed candidate's ability to devote the expected amount of time in each case.